Mocravimod

Mocravimod is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod retains T cell effector function. Mocravimod can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) [1][2][3][4].

Product Specifications

CAS Number

[509092-16-4]

Product Name Alternative

KRP-203 (free base)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt; GSK-3; JAK; LPL Receptor; Reactive Oxygen Species (ROS) ; STAT

Type

Reference compound

Related Pathways

Epigenetics; GPCR/G Protein; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/mocravimod.html

Purity

98.39

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OCC(CCC1=CC=C(SC2=CC=CC(OCC3=CC=CC=C3)=C2)C=C1Cl)(N)CO

Molecular Formula

C24H26ClNO3S

Molecular Weight

443.99

Precautions

H302, H315, H319, H335

References & Citations

[1]Simone Dertschnig, et al. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy. Transplant Cell Ther. 2023 Jan;29 (1) :41.e1-41.e9. |[2]Dertschnig S, et al. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy. Transplant Cell Ther. 2023 Jan;29 (1) :41.e1-41.e9.|[3]Suzuki et al. PS11.7: Mocravimod, a novel immunosuppressant, not only suppresses immune rejection but also promotes engraftment of intraportally transplanted islets by its anti-inflammatory and anti-coagulant effects.|[4]Potì F, et al. Mocravimod, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice. Arterioscler Thromb Vasc Biol. 2013 Jul;33 (7) :1505-12.|[5]Wu N, et al. The novel sphingosine-1-phosphate receptor modulator Mocravimod prevents myocardial ischemia-reperfusion injury by preserving mitochondrial function through activation of the RISK and SAFE signaling pathways. Cell Biol Toxicol. 2025 Nov 27;41 (1) :159.